ProPhase Labs Announces Collaboration with Forward Healthcare Consultants to Aid in the Commercialization of its Billion Dollar Potential BE-Smart Esophageal Cancer Test
13. August 2024 08:00 ET
|
ProPhase Labs, Inc.
GARDEN CITY, NY, Aug. 13, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH), a next-generation biotech, genomics, and diagnostics company, today reported its collaboration with Forward...
Biostage Appoints Ron Packard to Board of Directors
10. April 2023 09:30 ET
|
Biostage, Inc.
HOLLISTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Biostage, Inc. (OTCQB: BSTG) ("Biostage" or the "Company"), a cell-therapy biotechnology company with successful first-in-human experience in...
Stella Diagnostics CEO Discusses Competitive Advantage in Early Cancer Detection During Audio Interview with SmallCapVoice.com
15. Februar 2022 08:00 ET
|
Stella Diagnostics, Inc. and SmallCapVoice.com
AUSTIN, Texas, Feb. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new interview with Dr. Joe Abdo, CEO of Stella Diagnostics Inc. (OTC Pink: SLDX) (“the...
Extremely Robust Esophageal Cancer Pipeline Expected to Change the Pace of Cancer Treatment as Many Critical Pharma Companies are Proactively Participating in Developing Novel Therapies Estimates DelveInsight
05. Oktober 2021 20:00 ET
|
DelveInsight Business Research LLP
Las Vegas, USA, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Extremely Robust Esophageal Cancer Pipeline Expected to Change the Pace of Cancer Treatment as Many Critical Pharma Companies are Proactively...
NOTICE TO DISREGARD -- CDx Diagnostics
04. Mai 2021 11:13 ET
|
CDx Diagnostics
SUFFERN, N.Y., May 04, 2021 (GLOBE NEWSWIRE) -- We are advised by CDx Diagnostics that journalists and other readers should disregard the news release, “CDx Diagnostics Contracts with Wellmark Blue...
WATS3D Receives Medically Necessary Designation from Blue Cross Blue Shield of Kansas City
09. März 2021 11:00 ET
|
CDx Diagnostics
SUFFERN, N.Y., March 09, 2021 (GLOBE NEWSWIRE) -- WATS3D, a diagnostic platform used by physicians to detect Barrett’s esophagus (BE), pre-cancer and cancerous cells in the esophagus, has received a...
WATS3D Now Considered Medically Necessary by BlueCross BlueShield of South Carolina
26. Januar 2021 14:00 ET
|
CDx Diagnostics
SUFFERN, N.Y., Jan. 26, 2021 (GLOBE NEWSWIRE) -- WATS3D, an AI-powered diagnostic platform developed by CDx Diagnostics to identify precancerous and cancerous cells in the esophagus, is now...
CDx Diagnostics Awarded Federal Supply Schedule Contract
15. Dezember 2020 11:30 ET
|
CDx Diagnostics
Veterans now have access to WATS3D life-saving technology in the VA and community settings SUFFERN, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics has been awarded GSA Contract...
Study Confirms WATS3D as Cost-Effective Adjunct to Seattle Protocol
25. August 2020 13:00 ET
|
CDx Diagnostics
The addition of WATS3D to the screening process for BE resulted in approximately 3 fewer cancers and 3 fewer cancer deaths per 1,000 people screened SUFFERN, N.Y., Aug. 25, 2020 (GLOBE NEWSWIRE) --...
CDx Diagnostics Announces Contract with Hawaii Medical Services Association
11. August 2020 14:30 ET
|
CDx Diagnostics
WATS3D diagnostic platform for screening and surveillance ofBarrett’s esophagus now available to 800,000 members SUFFERN, N.Y., Aug. 11, 2020 (GLOBE NEWSWIRE) -- CDx Diagnostics, Inc. is now...